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Abstract
Background: Mucin 4 (MUC4) plays an important role in protecting and lubricating the epithelial surface of
reproductive tracts, but its role in the pathogenesis of endometriosis is largely unknown.
Methods: To correlate MUC4 polymorphism with the risk of endometriosis and endometriosis-related infertility, we
performed a case-control study of 140 patients and 150 healthy women. Six unique single-nucleotide
polymorphisms (SNPs) (rs882605, rs1104760, rs2688513, rs2246901, rs2258447 and rs2291652) were selected for this
study. DNA fragments containing the target SNP sites were amplified by polymerase chain reaction using the
TaqMan SNP Genotyping Assay System to evaluate allele frequency and distribution of genotype in MUC4
polymorphisms.
Results: Both the T/G genotype of rs882605 and the frequency of haplotype T-T (rs882605 and rs1104760) were
higher in patients than in controls and were statistically significant. The frequency of the C allele at rs1104760, the
C allele at rs2688513, the G allele at rs2246901 and the A allele at rs2258447 were associated with advanced stage
of endometriosis. Moreover, the G allele at rs882605 was verified as a key genetic factor for infertility in patients.
Protein sequence analysis indicated that amino acid substitutions by genetic variations at rs882605, rs2688513 and
rs2246901 occur in the putative functional loops and the type D von Willebrand factor (VWFD) domain in the
MUC4 sequence.
Conclusions: MUC4 polymorphisms are associated with endometriosis development and endometriosis-related
infertility in the Taiwanese population.
Background
Endometriosis is a common chronic gynecological dis-
ease characterized by the presence of endometrial gland
and stroma outside the uterine cavity, affecting approxi-
mately 10% of reproductive age women [1,2]. The com-
mon clinical symptoms include pelvic pain, heavy
menstrual bleeding, pelvic adhesion, bloating and fati-
gue. Notably, the prevalence of endometriosis is 0.5% to
5% in fertile women and 25% to 40% in infertile women
[3], suggesting infertility as one possible consequence of
endometriosis. To date, the implantation theory is
widely accepted, stating that endometrial tissues pass
through the fallopian tube, then attach and grow on pel-
vic tissue. However, this hypothesis cannot explain the
existence of endometriosis outside the pelvis or how
endometriosis progresses and invades other tissues.
Additional factors such as genetic or immune differ-
ences have been suggested as possible contributors to
trigger the formation of endometriosis [4-6]. Family his-
tory and genome-wide linkage studies also support
genetic predisposition during the development of endo-
metriosis [7-10]. These studies provide molecular evi-
dence demonstrating endometriosis as a genetic disease,
and it is desirable to explore more genetic variations
associated with endometriosis.
Similarly to malignant diseases, extensive growth of
endometrial cells on the peritoneal surface and invasion
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opment of endometriosis. This process is frequently
associated with several mechanisms involved in angio-
genesis and cellular adhesion. In fact, women who have
endometriosis appear to be more at risk of developing
several different kinds of ovarian cancers [8,11-13]. An
epidemiological study showed that the prevalence rates
of endometriosis in patients with endometrioid and
clear cell ovarian carcinoma are 19 and 35.9, respectively
[14]. These findings suggest that endometriosis and cer-
tain types of ovarian cancer may share several common
genetic alterations during pathogenesis. Genes that regu-
late cell mobility and invasion in ovarian cancers are
therefore possible candidates for playing roles in
endometriosis.
Mucins are high-molecular-weight glycoproteins with
the function of protecting and lubricating the epithelial
surface of respiratory, gastrointestinal and reproductive
tracts [15]. Among the mucin proteins, mucin 4
( M U C 4 )a n dm u c i n1( M U C 1 )a r et h em a j o ro n e s
expressed in the endometrial epithelium [16,17]. In
cancer studies, these two mucins have been shown to be
aberrantly expressed in various malignancies and have
been validated as novel targets for cancer diagnosis and
therapy [18-20]. Distinct from MUC1, the extracellular
domain of MUC4 can interact with human epidermal
growth factor receptor 2 (HER2) on the cell surface and
modulate downstream cell growth signaling by stabiliz-
ing and/or enhancing the activity of cell growth receptor
complexes [18,21,22]. Consequently, changes of
cytoarchitectures and cellular signaling may lead to the
increase of cell mobility and tumor cell invasion.
The above findings provide us with clues to hypothe-
size that genetic variations in the extracellular domain
of MUC4, especially those resulting in amino acid sub-
stitutions, may play roles involved in the development of
endometriosis. With endometriosis as a possible cause
of infertility in women, we also would like to study the
association of MUC4 single-nucleotide polymorphisms
(SNPs) with susceptibility to endometriosis-related
infertility.
Methods
Study population
A total of 140 individuals who underwent surgery for
benign diseases and pathology-proven endometriosis
were identified at China Medical University Hospital
from 1998 to 2008 and were enrolled in this study. In
general, these patients were diagnosed with ovarian cysts
on the basis of sonography and had several clinical symp-
toms related to endometriosis, including dysmenorrhea,
lower abdominal pain, infertility or abnormal menstrua-
tion. Study patients who failed to have pathology-proven
endometriosis were excluded from this study. For the
control group, blood samples of 150 healthy women were
selected from a pool of individuals who received regular
heath checkups at the same hospital and were identified
as normal on the basis of the examinations conducted.
A total of 142 controls were frequency-matched on the
basis of age profile with the study patients (Additional
file 1, Table S1). Controls who showed one of the endo-
metriosis-associated symptoms, even though the results
of their health checkups were normal, were excluded
from this study. This study was approved by the institu-
tional review board at China Medical University, with
informed consent obtained from each patient.
Clinical stages and association study
Clinical information on patients was collected from clin-
ical notes, including clinical stage, lesion size, location,
drug treatment and fertility (Additional file 1, Table S1).
The definition of endometriosis staging was based on
the classification of the American Society for Reproduc-
tive Medicine: Stage 1, minimal; Stage 2, mild; Stage 3,
moderate; and Stage 4, severe [23].
Genomic DNA extraction and genotyping of SNPs in
MUC4
Genomic DNA was extracted from peripheral blood leu-
kocytes according to standard protocols (Genomic DNA
kit; Qiagen, Valencia, CA, USA). DNA fragments con-
taining the target SNP sites were amplified by polymer-
ase chain reaction (PCR) assay using the TaqMan SNP
Genotyping Assay System from Applied Biosystems, Inc.
(Carlsbad, CA, USA). The probe search and design are
available on the Applied Biosystems, Inc. website [24].
Additional file 1, Table S2, lists probe identifications
for the six SNPs tested. PCR amplification conditions
consisted of initial denaturation at 95°C for 5 minutes
followed by 40 cycles at 95°C for 10 seconds, 56°C for
10 seconds and 72°C for 20 seconds, with one additional
cycle at 72°C for 5 minutes. Genetic variations were
detected by reading the fluorescence signals of PCR pro-
ducts. A positive signal indicates a perfect match
between the probe and the tested DNA, thus identifying
the allele types. Ten percent of study participants were
randomly chosen and genotyped in duplicate to confirm
the concordance of the genotyping results. In our study,
the call rates for these SNP probes were above 94%
(Additional file 1, Table S3).
Statistical analysis
The allelic frequency and genotype frequency distribu-
tions for the six polymorphisms of patients with endo-
metriosis and the controls were performed by c
2
analysis using SPSS software (version 10.0; SPSS Inc.,
Chicago, IL, USA). An unordered, 2 df two-sided test
was used for the statistical analyses of our genotyping
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Allelic and genotypic frequencies are expressed as per-
centages of total alleles and genotypes. Odds ratios
(ORs) were calculated from allelic and genotype fre-
quencies with 95% confident intervals (95% CIs). The
major (also the wild-type) allele was used as the refer-
ence for the allelic analyses. For the genotypic analyses,
the homozygous major allele genotype was used as the
referent group. Adherence to the Hardy-Weinberg equi-
librium (HWE) constant was tested using a c
2 test with
1 df. To study the association of the six SNPs with clini-
cal stages and reproductive ability, Fisher’s exact tests
instead of c
2 tests were used because of the small num-
ber of participants tested.
The haplotypes of each individual were determined
using the Bayesian statistical method available in the
free download software program PHASE 2.1 [25]. This
approach incorporates ap r i o r iexpectations of haploty-
pic structure based on population genetics and coales-
cence theory. Lewontin’sD ’ (|D’|) and the linkage
disequilibrium (LD) coefficient r
2 were determined
between selected pairs of biallelic loci [26]. Haploview
version 3.2 software (Whitehead Institute for Biomedical
Research, Cambridge, MA, USA) was used to examine
the structure of the LD block [27]. This program uses
two-marker expectation maximization to estimate the
maximum likelihood values of the four gamete frequen-
cies from which the D’ and log of odds (LOD) values
are derived. The genetic effects of the inferred haplo-
types were analyzed in the same way as the analysis of
polymorphisms. The reported haplotype percentages are
estimated on the basis of allele frequencies and LD. The
P values are based on a comparison of a given haplotype
with all other haplotypes combined.
Functional analyses and secondary structure predictions
of MUC4 protein
Functional characterization and annotation of MUC4
were performed by aligning the sequence with func-
tional motifs and/or signatures in the PROSITE protein
domain database [28]. To predict the secondary struc-
ture of the MUC4 sequence, the Chou and Fasman
method was used [29]. An improved method was
applied to increase the accuracy of the predictions by
locating nucleation regions with refined wavelet trans-
formation technology and by calculating propensity fac-
tors with larger data sets [30]. The program gives the
propensity of each residue to be a part of an a-helix, a
b-strand or a loop. We considered propensities Pa >
1.03 as significant for helices and propensities Pb >1 . 0 5
as significant for strands. Predicted regions with fewer
than four contiguous residues were not considered sec-
ondary structure units. For a region with both helix and
strand tendencies, the secondary structure conformed
with higher propensity: Pa >Pb or Pb >Pa is predicted.
To plot hydrophobicity and surface probability, the Kyte
and Doolittle method [31] and Emini et al. surface
accessibility prediction (SAP) [32] were used, respec-
tively. We slid a window along the MUC4 sequence to
assign a “hydrophobicity” or “surface probability” value
to each amino acid. The values were summed in the
window, and the results were plotted.
Results
MUC4 gene polymorphisms and endometriosis
Six SNPs in the extracellular domain of the MUC4 gene
with a frequency greater than 20% in Chinese Han Beij-
ing were selected from International HapMap Project
databank [33] (Additional file 1, Table S2). Genotypic
analyses (Figure 1) indicated rs882605 as a unique SNP
with a higher frequency of the TG genotype in patients
than in controls (P = 0.04, OR = 1.97, 95% CI, 1.17 to
3.32) (Table 1), while allele type analyses of these SNPs
showed no statistical significance. Of note, the major
(also the wild-type) allele w a su s e da st h er e f e r e n c ef o r
the allelic analyses. For the genotypic analyses, the
homozygous major allele genotype was used as the
referent group. To confirm the genetic impact of SNPs
on endometriosis, the top two high-risk alleles at
rs882605 and rs1104760 were selected for haplotype
analyses. Significantly, the frequency of haplotype T-T
was found to be higher in patients than in controls (P =
0.0353) (Table 2) (Additional file 2, Figure S1), suggest-
ing the association of MUC4 SNPs with endometriosis
development. The genotyping results were confirmed in
duplicate, and the concordance of duplicates was 97.6%.
Association of MUC4 gene polymorphisms and stages
We next asked whether MUC4 genetic variations could
possibly associate with clinical stages. Patients were
divided into two groups: the mild stage group with
patients at stages 1 or 2 and the advanced group with
patients at stages 3 or 4. Strikingly, genotype analyses
revealed strong associations of CC type at rs2688513 (P =
0.04) and GG type at rs2246901 (P = 0.03), with more
advanced endometriosis at stage 3 or 4 (Table 3). Domi-
nant effects were found for other genetic variations at
rs1104760 (CC + CT versus TT) and rs2258447 (AA +
AG versus GG) during endometriosis progression. Allele
type analyses suggested C allele at rs1104760, C allele at
rs2688513, G allele at rs2246901 and A allele at
rs2258447 as risk factors that correlated with more
severe endometriosis.
MUC4 gene polymorphisms and infertility
Since endometriosis has been suspected as one potent
factor leading to infertility in women [3], we also studied
the possible linkage between MUC4 SNPs and infertility.
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type association study, our data indicated T allele at
rs882605 as a protective factor that associated with
reduced frequency of infertility in patients with endome-
triosis (Table 4). Two other alleles, C at rs2688513 and G
at rs2246901, showed similar protective effects, but the
data did not reach statistical significance. Of note, the
major (also the wild-type) allele was used as the reference
for the allelic analyses. For the genotypic analyses, the
homozygous major allele genotype was used as the refer-
ent group. In our haplotype analyses, we thus sought to
ascertain the impact of the genetic combination of these
top three protective alleles. Table 5 indicates that patients
with haplotype T-C-G did show a lower frequency of
infertility, although the results did not show a statistically
significant difference (P = 0.099). By contrast, haplotype
G-T-T showed a strong association with infertility
in patients (P = 0.012) (Table 5) (Additional file 2,
Figure S2) and could be used as a risk indicator for
patients at higher risk of developing severe complications
such as infertility.
MUC4 gene polymorphisms and amino acid substitutions
Because these endometriosis-associated SNPs can cause
amino acid substitutions (Additional file 1, Table S2),
the biofunctions of MUC4 might be altered by changes
in hydrophilicity and protein folding. Figure 2 illustrates
the functional domains in MUC4 protein sequence and
secondary structures that contain these SNPs. Our data
show that genetic variations of rs882605 and rs2688513
cause amino acid substitutions in long-loop regions
(> 10 residues) between secondary structure units
(a-helices or b-strands) with high hydrophilicity and
moderate surface probability (Figure 2). Amino acid
composition analyses also revealed that these two loops
(300-319 and 4,134-4,158) contain several negatively
charged aspartate (D) residues and reverse turn ele-
ments, glycine (G) and proline (P), suggesting the
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Figure 1 Allelic discrimination plots of the six tested single-nucleotide polymorphisms (SNPs) in the mucin 4 (MUC4)g e n e .T h eD N A
samples from patients and controls were genotyped by using the TaqMan SNP Genotyping Assay System. The major (also the wild-type) alleles
were detected by 6-carboxyfluorescein (FAM)-labeled probes (blue), and the minor alleles were detected by 2’-chloro-7’-phenyl-1,4-dichloro-6-
carboxyfluorescein (VIC)-labeled probes. The genotyping results of the six SNPs in the MUC4 gene are presented as allelic discrimination plots. Of
note, the intensity of FAM signals tended to be similar among samples in our assays, thus the dots for a wild-type genotype overlapped each
other. “X” indicates the participant who failed to be genotyped.
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tional regulation [34,35]. In addition, rs2246901 locates
in a type D von Willebrand factor (VWFD) domain
responsible for protein-protein interaction and cell
adhesion and/or migration [36,37]. Our findings support
the functional roles of MUC4 SNPs in regulating
cellular mobility and invasion of endometrial cells dur-
ing endometriosis development and progression.
Discussion
Previous studies have shown polymorphism of cytokines
and adhesion molecules which were associated with the
pathogenesis of endometriosis [38,39]. To the best of
our knowledge, however, no other study to date has
investigated the possible association of MUC4 and endo-
metriosis. The purpose of this study was to evaluate
whether genetic variations in MUC4 associate with
endometriosis in the Taiwanese population. Our data
prove the association of MUC4 polymorphisms with
advanced stages of endometriosis and the related inferti-
lity. Since the extracellular domain of MUC4 is critical
for HER2 interaction and cell invasiveness, these defined
SNPs located in putative functional domains of MUC4
Table 1 Genotype and allele distributions of the six SNPs in the MUC4 gene in Taiwanese endometriosis patients and
controls
a
SNPs Genotype/allele No. (%)of patients HWE No. (%)of controls HWE P value OR (95% CI)
rs882605 TT 9 (7.0) 0.62 10 (7.2) 0.07 0.04 1.13 (0.43 to 3.00)
TG 54 (42.2) 40 (28.8) 1.97 (1.17 to 3.32)
b
GG 65 (50.8) 89 (64.0) 1.00 Reference
T 72 (28.1) 60 (21.6) 0.08 1.42 (0.96 to 2.11)
G 184 (71.9) 218 (78.4) 1.00 Reference
rs1104760 CC 7 (5.4) 0.94 9 (6.3) 0.09 0.30 0.96 (0.33 to 2.82)
CT 47 (36.2) 39 (27.5) 1.49 (0.89 to 2.51)
TT 76 (58.5) 94 (66.2) 1.00 Reference
C 61 (23.5) 57 (20.1) 0.34 1.22 (0.81 to 1.84)
T 199 (76.5) 227 (79.9) 1.00 Reference
rs2246901 GG 8 (6.0) 0.96 10 (7.1) 0.15 0.56 0.91 (0.33 to 2.53)
TG 49 (36.6) 43 (30.5) 1.30 (0.78 to 2.17)
TT 77 (57.5) 88 (62.4) 1.00 reference
G 65 (24.3) 63 (22.3) 0.60 1.11 (0.75 to 1.65)
T 203 (75.7) 219 (77.7) 1.00 Reference
rs2258447 AA 9 (6.4) 0.37 10 (7.0) 0.07 0.70 1.02 (0.38 to 2.77)
AG 44 (32.1) 40 (28.2) 1.25 (0.74 to 2.11)
GG 81 (61.4) 92 (64.8) 1.00 Reference
A 62 (22.5) 60 (21.1) 0.57 1.12 (0.75 to 1.68)
G 206 (77.5) 224 (78.9) 1.00 Reference
rs2291652 CC 11 (8.7) 0.92 11 (8.4) 0.26 0.52 1.17 (0.46 to 2.96)
CT 52 (40.9) 45 (34.4) 1.35 (0.81 to 2.28)
TT 64 (50.4) 75 (57.3) 1.00 Reference
C 74 (29.1) 67 (25.6) 0.36 1.20 (0.81 to 1.76)
T 180 (70.9) 195 (74.4) 1.00 Reference
rs2688513 CC 8 (6.0) 0.62 10 (7.0) 0.09 0.66 0.91 (0.33 to 2.53)
TC 45 (33.8) 41 (28.9) 1.25 (0.74 to 2.10)
TT 80 (60.2) 91 (64.1) 1.00 Reference
C 61 (22.9) 61 (21.5) 0.68 1.09 (0.73 to 1.63)
T 205 (77.1) 223 (78.5) 1.00 Reference
aMUC4, mucin 4 gene; SNP, single-nucleotide polymorphism; OR, odds ratio; 95% CI, 95% confidence interval; HWE, P values of deviation from the Hardy-
Weinberg equilibrium constant. Allelic frequencies were determined by c
2 test using 2 × 2 contingency tables. Genotype frequencies were determined by c
2 test
using 2 × 3 contingency tables.
bP < 0.05 was considered statistically significant.
Table 2 Haplotype frequencies of MUC4 polymorphisms
in endometriosis patients and controls
a
rs1104760/rs882605 Patients, % Controls, % P value
TG 73.2 78.8 0.1202
CT 22.9 20.1 0.4134
TT 3.9 1.1 0.0353
b
aMUC4, mucin 4 gene. The reported haplotype percents are estimated
percents based on allele frequencies and the linkage disequilibrium. The P
values are based on a comparison of a given haplotype with all other
haplotypes combined.
bP < 0.05 was considered statistically significant.
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clinical stages
a
SNP Genotype/allele No. (%) at mild stage
b No. (%) at severe stage
c P value
rs882605 TT 0 (0.0) 7 (8.0) 0.25
TG 2 (25.0) 41 (46.6)
GG 6 (75.0) 40 (45.5)
TT+TG 2 (25.0) 48 (54.5) 0.11
GG 6 (75.0) 40 (45.5)
T 2 (12.5) 55 (31.3) 0.12
G 14 (87.5) 121 (68.8)
rs1104760 CC 0 (0.0) 5 (5.8) 0.05
CT 0 (0.0) 36 (41.9)
TT 7 (100.0) 45 (52.3)
CC+CT 0 (0.0) 41 (47.7) 0.0
d
TT 7 (100.0) 45 (52.3)
C 0 (0.0) 46 (26.7) 0.03
d
T 14 (100.0) 126 (73.3)
rs2688513 CC 0 (0.0) 6 (6.9) 0.04
d
CT 0 (0.0) 34 (39.1)
TT 8 (100.0) 47 (54.0)
CC+CT 0 (0.0) 40 (46.0) 0.01
d
TT 8 (100.0) 47 (54.0)
C 0 (0.0) 46 (26.4) 0.02
d
T 16 (100.0) 128 (73.6)
rs2246901 GG 0 (0.0) 6 (6.8) 0.03
d
TG 0 (0.0) 36 (40.9)
TT 8 (100.0) 46 (52.3)
GG+TG 0 (0.0) 42 (47.7) 0.01
d
TT 8 (100.0) 46 (52.3)
G 0 (0.0) 48 (27.3) 0.02
d
T 16 (100.0) 128 (72.7)
rs2258447 AA 0 (0.0) 7 (7.9) 0.08
AG 0 (0.0) 32 (36.0)
GG 7 (100.0) 50 (56.2)
AA+AG 0 (0.0) 39 (43.8) 0.02
d
GG 7 (100.0) 50 (56.2)
A 0 (0.0) 46 (25.8) 0.03
d
G 14 (100.0) 132 (74.2)
rs2291652 CC 0 (0.0) 7 (8.3) 0.61
CT 2 (33.3) 36 (42.9)
TT 4 (66.7) 41 (48.8)
CC+CT 2 (33.3) 43 (51.2) 0.40
TT 4 (66.7) 41 (48.8)
C 2 (16.7) 50 (29.8) 0.33
T 10 (83.3) 118 (70.2)
aSNP, single-nucleotide polymorphism; MUC4, mucin 4 gene. Allelic frequencies were determined by Fisher’s exact test using 2 × 2 contingency tables. Genotype
frequencies were determined by Fisher’s exact test using 2 × 3 contingency tables.
bMild stage, patients at clinical stage1 or stage 2;
cSevere stage, patients at
clinical stage 3 or stage 4;
dP < 0.05 was considered statistically significant.
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ment and progression.
The development of endometriosis and certain types
of ovarian cancer share several similar clinical features.
For example, endometriosis could progressively invade
pelvic viscera, resulting in adhesion, and could recur
after medical treatment or surgery. Because of the func-
tions involved in the acquisition of adhesion ligands or
receptors and the loss of antiadhesion, proteins such as
MUC4 and MUC1, the two major mucins present in
endometrial epithelium, thus become suspect in endo-
metriosis development [16,17]. In addition to gene over-
expression, genetic variations in MUC1 have also been
reported as risk factors contributing to cell mobility and
the severity of cancer [40-43]. However, the influence of
MUC4 genetic variations on cell behavior remains
unclear. In this study, Pro4135Ser (rs2688513) and
Ala4693Ser (2246901) substitutions in the putative func-
tional domains of MUC4 were found to be associated
with advanced stages of endometriosis. Since MUC4 is
an emerging target for ovarian cancer [18,19,44,45], our
Table 4 Genotype and allele distributions of the six SNPs in the MUC4 gene in endometriosis patients with different
reproductive ability
a
SNP Genotype/allele No. (%) infertility No. (%) noninfertility P value OR (95% CI)
rs882605 TT 0 (0.0) 8 (8.7) 0.07 - -
TG 5 (26.3) 42 (45.7) 0.36 (0.12 to 1.08)
GG 14 (73.7) 42 (45.7) 1.00 Reference
T 5 (13.2) 58 (31.5) 0.03
b 0.33 (0.12 to 0.89)
G 33 (86.8) 126 (68.5) 1.00 Reference
rs1104760 CC 0 (0.0) 6 (6.3) 0.41 - -
CT 4 (25.0) 37 (38.5) 0.48 (0.14 to 1.60)
TT 12 (75.0) 53 (55.2) 1.00 Reference
C 4 (12.5) 49 (25.5) 0.12 0.42 (0.14 to 1.25)
T 28 (87.5) 143 (74.5) 1.00 Reference
rs2688513 CC 0 (0.0) 7 (7.4) 0.32 - -
TC 5 (25.0) 34 (36.2) 0.52 (0.17 to 1.56)
TT 15 (75.0) 53 (56.4) 1.00 Reference
C 5 (12.5) 48 (25.5) 0.09 0.42 (0.15 to 1.12)
T 35 (87.5) 140 (74.5) 1.00 Reference
rs2246901 GG 0 (0.0) 7 (7.4) 0.25 - -
TG 5 (25.0) 37 (38.9) 0.46 (0.15 to 1.38)
TT 15 (75.0) 51 (53.7) 1.00 Reference
G 5 (12.5) 51 (26.8) 0.06 0.39 (0.14 to 1.05)
T 35 (87.5) 139 (73.2) 1.00 Reference
rs2258447 AA 1 (5.0) 7 (7.3) 0.41 0.53 (0.05 to 5.53)
AG 4 (20.0) 33 (34.4) 0.45 (0.14 to 1.48)
GG 15 (75.0) 56 (58.3) 1.00 Reference
A 6 (15.0) 47 (24.5) 0.22 0.54 (0.22 to 1.38)
G 34 (85.0) 145 (75.5) 1.00 Reference
rs2291652 CC 0 (0.0) 7 (7.8) 0.29 - -
CT 7 (35.0) 40 (44.4) 0.58 (0.21 to 1.60)
TT 13 (65.0) 43 (47.8) 1.00 Reference
C 7 (17.5) 54 (30.0) 0.12 0.49 (0.21 to 1.19)
T 33 (82.5) 126 (70.0) 1.00 Reference
aSNP, single-nucleotide polymorphism; MUC4, mucin 4 gene; OR, odds ratio; 95% CI, 95% confidence interval. Allelic frequencies were determined by Fisher’s
exact test using 2 × 2 contingency tables. Genotype frequencies were determined by Fisher’s exact test using 2 × 3 contingency tables.
bP < 0.05 was considered
statistically significant.
Table 5 Haplotype frequencies of MUC4 polymorphisms
in endometriosis patients with infertility
a
rs882605/rs2246901/
rs2688513
Infertility,
%
Noninfertility,
%
P
value
GTT 87.2 67.4 0.012
b
TGC 12.5 24.4 0.099
TTT 0.2 4.4 0.206
GGT 0.0 2.2 0.344
aMUC4, mucin 4 gene. The reported haplotype percentages are estimated
percentages based on allele frequencies and the linkage disequilibrium. The
P values are based on a comparison of a given haplotype with all other
haplotypes combined.
bP < 0.05 was considered statistically significant.
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the roles of MUC4 in the development of gynecological
disorders.
To study the genetic effects of mucin proteins by
SNPs, the major interest focuses on the variable number
of tandem repeat (VNTR) polymorphisms, which result
in different-sized gene transcripts. For examples, MUC1
variations in the VNTR domain have been found to play
roles in regulating Helicobacter pylori binding to gastric
cells [46]. Other studies have also concluded that VNTR
polymorphisms can influence T-antigen presentation
and the local immune responses, which consequently
have potential effects on gastric cancer development
[47,48]. With regard to MUC4, a high degree of poly-
morphism in the VNTR domain was observed in human
tissues, including the endometrial epithelium [49,50].
However, the different-sized MUC4 transcripts did not
show association with embryo implantation or cancer
development. By contrast, MUC4 can promote cell pro-
liferation and antiapoptotic effects in cancer cells by
interacting with HER2 on the cell surface [18,19,22],
suggesting the potency of functional domains in the
extracellular domain of MUC4. In this study, two SNPs
(rs2688513 and rs2246901) that locate in a putative
functional loop and the VWFD protein binding domain,
respectively, were found to be associated with advanced
stages of endometriosis. Further study may clarify
whether these amino acid substitutions could change
the interaction with HER2 and/or play crucial roles in
regulating the cellular activity of the spread of
endometriosis.
Endometriosis could cause pelvic adhesion and tubal
occlusion that may lead to infertility. However, among
patients with endometriosis-related infertility, 50% to
60% of them were diagnosed with minimal or mild
endometriosis [3]. Impaired folliculogenesis, bad oocyte
1. 4269-4424 NIDO
2. 4425-4540 AMOP
3. 4553-4788 VWFD
4. 4990-5029 EGF_3
5. 5193-5232 EGF_3
6. 5241-5261 transmembrane
MUC4: total 5284 a.a. 1  2  3                                    4    5 6
rs882605                                                  rs2688513                                         rs2258447
rs1104760                                                    rs2246901                                rs2291652
Alpha, Regions - Chou-Fasman A
Beta, Regions - Chou-Fasman B
Turn, Regions - Chou-Fasman T
Hydrophilicity Plot - Kyte-Doolittle 0
2.04
-1.82
Surface Probability Plot - Emini 1
6
0
Alpha, Regions - Chou-Fasman A
Beta, Regions - Chou-Fasman B
Turn, Regions - Chou-Fasman T
Hydrophilicity Plot - Kyte-Doolittle 0
1.87
-1.3
Surface Probability Plot - Emini 1
6
0
Alpha, Regions - Chou-Fasm A
Beta, Regions - Chou-Fasm B
Turn, Regions - Chou-Fasm T
Hydrophilicity Plot - Kyte-Do 0
2.7
-2
Surface Probability Plot - Em 1
6
0
D-helix
E-strand
turn/loop
hydro-
philicity
surface
probability
MUC4
sequence
251 a.a. ~ 400 a.a.              4001 a.a. ~ 4200 a.a.            4601 a.a. ~ 4800 a.a.
Phe(300)Val   Thr(377)Ile                                 Pro(4135)Ser                     Ala(4693)Ser
300-FDPEGQSPATFSRTSTQDTT-319 4134-TPGMTTPSLKTDGGRRTATSPPPTT-4158
Figure 2 Functional domains in the MUC4 protein sequence and the predicted secondary structures. Six functional domains and/or
signatures (boxes) were annotated by aligning MUC4 protein sequence in PROSITE protein domain database [28]. The boundaries of each
signature are listed. Among six SNPs tested in this study (stars), rs882605 and rs2688513 (black) were found in two different long-loop regions,
300-319 and 4,134-4,158, respectively (bold letters refer to amino acid substitution sites). The SNP rs2246901 (gray) was found in a type D von
Willebrand factor (VWFD) domain. The MUC4 reference sequence can be located at National Center for Biotechnology Information databank
NP_060876.4.
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Page 8 of 10quality and impaired implantation of embryo are there-
fore considered to be the possible mechanisms for
endometriosis-related infertility. Changes in cytokines
and growth factors in endometrium, follicular fluid
and peritoneal fluid have been suggested as the key
players for inducing the above-mentioned phenomena
[5]. Recently, several studies have shown that MUC4
could promote cell migration, change the endometrial
environment and create weak points in the epithelium,
thus facilitating the failure of embryo implantation
[50,51]. The Carraway et al.[ 5 2 ]s t u d ya l s os h o w e d
that embryo implantation was associated with downre-
gulation of MUC4 expression in an animal model. In
this study, women with a T allele in rs882605 had a
lower risk of endometriosis-related infertility, whereas
rs2688513 and rs2246901 SNPs did not show any asso-
ciation with the reproductive ability of patients. The
rs882605 SNP locates in a putative functional loop
within the VNTR domain of MUC4 that may control
T-cell antigen presentation and the local immune
responses. Our findings may support the view that the
regulation of local immunity, rather than uncontrolled
cell proliferation, in the endometrium may play a more
important role in the development of endometriosis-
related infertility.
Our study shows that the T/G genotype at rs882605,
as compared with the T/T or G/G genotypes, is unique
in patients with endometriosis. So far, our data cannot
provide sufficient information to explain why the T/T
genotype does not show higher risk of endometriosis
than T/G. One reason could be the relatively small
study group, while other possibilities could exist. For
example, the SNPs analyzed are in tight LD with other
unknown allele variants which have an opposite effect.
In this case, only individuals with the T/G heterozygous
genotype could be observed. Because this is a hospital-
based study with a modest sample size, enrollment of a
larger cohort based on a population approach could
help to elucidate the functional role of MUC4 in endo-
metriosis and the related infertility.
Conclusions
In this study, we observed an association of MUC4
polymorphism with endometriosis development and
endometriosis-related infertility in a Taiwanese popula-
tion. However, the true mechanism of how MUC4
modulates the pathogenesis of endometriosis and infer-
tility was not clearly understood. In addition, the risk
SNPs pose for endometriosis stages and infertility
differ, suggesting dissimilar molecular mechanisms
for these clinical features. More detailed studies
are needed to investigate the biochemical pathways
regulated by MUC4 during the development of
endometriosis.
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